Ciclosporin Eye Drops in Ocular Graft-Versus-Host Disease: A Case Report
Published: 2024-04-29
Page: 102-106
Issue: 2024 - Volume 7 [Issue 1]
EL Filali EL Mehdi *
Department of Ophthalmology, Cadi Ayyad University, Med Vi University Hospital, Avicenne Military Hospital, Marrakech, Morocco.
Farah Benelkadri
Department of Ophthalmology, Cadi Ayyad University, Med Vi University Hospital, Avicenne Military Hospital, Marrakech, Morocco.
Houssaine Ait Lhaj
Department of Ophthalmology, Cadi Ayyad University, Med Vi University Hospital, Avicenne Military Hospital, Marrakech, Morocco.
Mohamed Kriet
Department of Ophthalmology, Cadi Ayyad University, Med Vi University Hospital, Avicenne Military Hospital, Marrakech, Morocco.
Fouad EL Asri
Department of Ophthalmology, Cadi Ayyad University, Med Vi University Hospital, Avicenne Military Hospital, Marrakech, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Aims: To report a case of severe ocular graft-versus-host disease (GVHD) managed with topical ciclosporin.
Introduction: Ocular graft-versus host disease is a rare and often misdiagnosed aetiology of dry eye syndrome.
Case: We report a case of young women presenting with a severe and bilateral ocular surface inflammation with filamentous keratitis, posterior blepharitis, Meibomian gland dysfunction and neovascular invasion. Ocular GVHD was diagnosed due to severe dry eye symptoms and a history of allogeneic haematopoietic stem cell transplantation. Immunosuppressive treatment resulted in a spectacular anatomical and clinical improvement, rapid resolution of symptoms and improvement in visual acuity.
Conclusion: Ocular GVHD should be considered in any severe dry eye syndrome associated with allogeneic bone marrow transplantation. Topical immunosuppressive therapies have revolutionised the curative management of these patients.
Keywords: Dry eye syndrome, ocular graft-versus-host disease, topical ciclosporin treatment, prevention
How to Cite
Downloads
References
Nassiri N, Eslani M, Panahi N, Mehravaran S, Ziaei A, DjalilianAR. Ocular graft versus host disease following allogeneic stemcell transplantation: a review of current knowledge and recommendations. J Ophthal Vis Res. 2013;8:351—8.
Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR,et al. Topical corticosteroid therapy for cicatricial conjunctivitisassociated with chronic graft-versus-host disease. Bone MarrowTransplant. 2004;33:1031—5.
Couriel D, Carpenter PA, Cutler C, Bola˜nos-Meade J, TreisterNS, Gea-Banacloche J, et al. Ancillary therapy and supportivecare of chronic graft-versus host disease: national institutes of health consensus development project on criteria for clinicaltrials in chronic graft-versus host disease: V. Ancillary Therapyand Supportive Care Working Group Project. Biol Blood MarrowTranspl. 2006;12:375—96.
Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: areview. Surv Ophthalmol. 2013;58:233—50.
Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A,et al. Treatment of ocular graft-versus-host-disease with topicalcyclosporine 0.05 %. Cornea. 2010; 29:1392—6.
Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117:6714--20
Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113:5074—82
Townley JR, Dana R, Jacobs DS. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. Semin Ophthalmol. 2011; 26:251—60
Perez RL, Perez-Simon JA, Caballero-Velazquez T, et al. Limbus damage in ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2011; 17:270—3
Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versushost disease. Blood. 2011; 117:2275—83.